Bempegaldesleukin

贝培阿地白介素

Report date: 2026/05/18 20:02:07

Base Information

Drug NameBempegaldesleukin
Drug Alias NameBempegaldesleukinumBEMPEGBMS-986321ONO-7911NKTR-214
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin-2 receptor beta chain agonists
TargetsInterleukin-2 receptor beta chain
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Skin MelanomaSolid tumours +[21
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[29
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNektar Therapeutics
China Registration ClassN/A

Develop Information

Active IndicationsSolid tumoursNeoplasm MetastasisUrinary Bladder Neoplasms +[6
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Skin MelanomaProstatic Neoplasms, Castration-Resistant +[15

Other Information

ATC CodeN/A
Related LinksN/A